Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Humira (Adalimumab) (Abbott Laboratories) for treatment of pediatric crohn disease. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2010 Authors' objectives <p>Crohn disease (CD) is a progressive, inflammatory bowel disease that can occur in any part of the digestive tract. While CD affects people of all ages, approximately 25% to 30% of all CD patients develop symptoms before the age of 20 years. In the United States, approximately 100,000 to 150,000 children aged = 17 years have CD, and the incidence of pediatric CD appears to be increasing. The cause of pediatric CD remains unclear, but it is thought to be a complex interaction among environmental, genetic, and immunoregulatory factors. There is no known cure for CD. Treatment may include medication, nutrition supplements, surgery, or a combination of these options. Tumor necrosis factor-alpha (TNF-a) is an inflammatory protein that is part of the body's natural inflammatory and immune response, but when produced in excess, plays a key role in the inflammatory responses of some autoimmune diseases. Increased levels of TNF-a have been found in stool, urine, and mucosal biopsy specimens from patients with active CD. Thus, targeted therapy against TNF-a has become a logical therapeutic option for patients with CD.</p> Timeliness warning This report has been archived and may contain outdated information. To request a copy of the report please contact the organisation directly. Indexing Status Subject indexing assigned by CRD MeSH Anti-Inflammatory Agents; Antibodies, Monoclonal; Child; Crohn Diseases Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com AccessionNumber 32011000817 Date abstract record published 15/06/2011 |